Skip to content
DataLookout
Menu

NCT07826676

Use of Bone Marrow Stem Cells (MesenCell) for the Treatment of Patients With Chronic Graft-versus-host Disease

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Start date pushed from Oct 2026 to Feb 2027
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of Participants With Treatment-Related Adverse Events
Timeframe: 30 days after the last MesenCell infusion

Secondary (8)

Overall Treatment Response Rate
Change in Overall Response
Change in Organ-Specific Response Scores
All-cause mortality
Failure-Free Survival
Show 3 moreShow less
Reduction in Corticosteroid Therapy
Discontinuation of Immunosuppressive Therapy
Time to Best Overall Response

Arms and interventions

MesenCellExperimental

Patient will receive 1 to 3 intravenous infusions of 2 × 10⁶/kg of Mesenchymal stem cells (MSCs) at 7 day intervals

Biologicals: Mesenchymal Stem Cell Infusion

Sites

4 sites in 1 country